These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36588414)

  • 41. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Live Attenuated
    Banerjee A; Bhattacharya P; Dagur PK; Karmakar S; Ismail N; Joshi AB; Akue AD; KuKuruga M; McCoy JP; Dey R; Nakhasi HL
    J Immunol; 2018 Jan; 200(1):163-176. PubMed ID: 29187586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 44. Engineering a vector-based pan-Leishmania vaccine for humans: proof of principle.
    Cecílio P; Oristian J; Meneses C; Serafim TD; Valenzuela JG; Cordeiro da Silva A; Oliveira F
    Sci Rep; 2020 Oct; 10(1):18653. PubMed ID: 33122717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
    Seyed N; Peters NC; Rafati S
    Front Immunol; 2018; 9():1227. PubMed ID: 29922288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical Assessment of the Immunogenicity of Experimental Leishmania Vaccines.
    Martins VT; Machado AS; Humbert MV; Christodoulides M; Coelho EAF
    Methods Mol Biol; 2022; 2410():481-502. PubMed ID: 34914064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.
    Avishek K; Kaushal H; Gannavaram S; Dey R; Selvapandiyan A; Ramesh V; Negi NS; Dubey US; Nakhasi HL; Salotra P
    Sci Rep; 2016 Sep; 6():33059. PubMed ID: 27624408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Leishmania donovani Ortholog of the Glycosylphosphatidylinositol Anchor Biosynthesis Cofactor PBN1 Is Essential for Host Infection.
    Roberts A; Nagar R; Brandt C; Harcourt K; Clare S; Ferguson MAJ; Wright GJ
    mBio; 2022 Jun; 13(3):e0043322. PubMed ID: 35420475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
    Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
    Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.
    Kumari S; Samant M; Khare P; Misra P; Dutta S; Kolli BK; Sharma S; Chang KP; Dube A
    Eur J Immunol; 2009 Jan; 39(1):178-91. PubMed ID: 19053149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
    Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
    Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
    Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leishmania vaccine development: exploiting the host-vector-parasite interface.
    Reed SG; Coler RN; Mondal D; Kamhawi S; Valenzuela JG
    Expert Rev Vaccines; 2016; 15(1):81-90. PubMed ID: 26595093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis.
    Kumari P; Mamud A; Jha AN
    Curr Drug Targets; 2023; 24(13):1023-1031. PubMed ID: 37823567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y; Jones DE
    Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
    Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
    Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
    Ribeiro PAF; Dias DS; Lage DP; Costa LE; Martins VT; Tavares GSV; Mendonça DVC; Lima MP; Oliveira JS; Steiner BT; Machado-de-Ávila RA; Roatt BM; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Teixeira AL; Coelho EAF
    Cell Immunol; 2018 Sep; 331():67-77. PubMed ID: 29871740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant effects of TLR agonist gardiquimod admixed with Leishmania vaccine in mice model of visceral leishmaniasis.
    Goyal DK; Keshav P; Kaur S
    Infect Genet Evol; 2021 Sep; 93():104947. PubMed ID: 34052416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.